Various molecular targeted agents such as anti-vascular endothelial growth factor (VEGF) monoclonal antibody (bevacizumab) and anti-epidermal growth factor receptor (EGFR) monoclonal antibody (cetuximab) have been developed for CRC therapy 2,3. This evidence concerns the gene EGFR and colorectal carcinoma.